- In March 2020, EA Pharma Co., Ltd., in collaboration with its parent company Eisai Co., Ltd., launched “Actonel 17.5 mg tablets,” which received approval from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of Paget's disease of bone. This launch represents a significant advancement in therapeutic options for managing this condition. By providing a targeted treatment, the companies aim to improve patient outcomes and enhance the overall management of Paget's disease
- In May 2021, Leucadia Pharmaceuticals Inc. introduced its FDA-approved generic product, Calcitonin Salmon Injection, USP, Synthetic. This injection is therapeutically equivalent to MIACALCIN and is indicated for the treatment of osteoporosis in postmenopausal women as well as for Paget's disease. Additionally, it is used in the early management of hypercalcemic emergencies, providing a rapid decrease in serum calcium levels when necessary
